UBS Group’s Franklin Genomic Advancements ETF HELX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $23.9K | Sell |
863
-1,798
| -68% | -$49.8K | ﹤0.01% | 7013 |
|
|
2025
Q1 | $71.9K | Buy |
2,661
+544
| +26% | +$14.7K | ﹤0.01% | 6031 |
|
|
2024
Q4 | $61.1K | Buy |
2,117
+1,668
| +371% | +$48.1K | ﹤0.01% | 5957 |
|
|
2024
Q3 | $14.6K | Buy |
449
+407
| +969% | +$13.2K | ﹤0.01% | 6333 |
|
|
2024
Q2 | $1.33K | Buy |
+42
| New | +$1.33K | ﹤0.01% | 7428 |
|
|
2024
Q1 | – | Sell |
-1,628
| Closed | -$49.6K | – | 8333 |
|
|
2023
Q4 | $49.6K | Buy |
1,628
+1,588
| +3,970% | +$48.4K | ﹤0.01% | 5338 |
|
|
2023
Q3 | $1.13K | Buy |
+40
| New | +$1.13K | ﹤0.01% | 6936 |
|
|
2023
Q1 | – | Sell |
-603
| Closed | -$18.2K | – | 8689 |
|
|
2022
Q4 | $18.2K | Sell |
603
-857
| -59% | -$25.8K | ﹤0.01% | 6582 |
|
|
2022
Q3 | $43K | Buy |
1,460
+214
| +17% | +$6.3K | ﹤0.01% | 5423 |
|
|
2022
Q2 | $40K | Sell |
1,246
-749
| -38% | -$24K | ﹤0.01% | 5075 |
|
|
2022
Q1 | $74K | Buy |
1,995
+707
| +55% | +$26.2K | ﹤0.01% | 5110 |
|
|
2021
Q4 | $62K | Buy |
+1,288
| New | +$62K | ﹤0.01% | 5631 |
|
|
2020
Q2 | – | Sell |
-3
| Closed | – | – | 7161 |
|
|
2020
Q1 | $0 | Buy |
+3
| New | – | ﹤0.01% | 7088 |
|